Formulations and methods of treating inflammatory bowel disease

Details Formulations and methods of treating inflammatory bowel disease Formulations and methods of treating inflammatory bowel disease

2004-09-01

2010-06-15

Anderson, Rebecca L (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ortho-hydroxybenzoic acid or derivative doai

C514S150000, C514S160000, C534S852000, C534S853000, C562S451000, C560S071000

Reexamination Certificate

active

07737133

ABSTRACT:
Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

REFERENCES:
patent: 4374932 (1983-02-01), Pitzele et al.
patent: 4496553 (1985-01-01), Halskov
patent: 4559330 (1985-12-01), Agback et al.
patent: 4591584 (1986-05-01), Agback
patent: 4608048 (1986-08-01), Cortese et al.
patent: 4627851 (1986-12-01), Wong et al.
patent: 4693895 (1987-09-01), Wong et al.
patent: 4705515 (1987-11-01), Wong et al.
patent: 4880794 (1989-11-01), Halskov
patent: 4904474 (1990-02-01), Theeuwes et al.
patent: 4980173 (1990-12-01), Halskov
patent: 5041431 (1991-08-01), Halskov
patent: 5541170 (1996-07-01), Rhodes et al.
patent: 5541171 (1996-07-01), Rhodes et al.
patent: 5681584 (1997-10-01), Savastano et al.
patent: 5716648 (1998-02-01), Halskov et al.
patent: 5840332 (1998-11-01), Lerner et al.
patent: 5866619 (1999-02-01), Sintov et al.
patent: 6004581 (1999-12-01), Jepsen et al.
patent: 6277412 (2001-08-01), Otterbeck
patent: 6506407 (2003-01-01), Watanabe et al.
patent: 6551620 (2003-04-01), Otterbeck
patent: 6602915 (2003-08-01), Uhrich
patent: 6733789 (2004-05-01), Stark et al.
patent: 6897205 (2005-05-01), Beckert et al.
patent: 6962717 (2005-11-01), Huber et al.
patent: 2001/0026807 (2001-11-01), Watts
patent: 2001/0036473 (2001-11-01), Scott et al.
patent: 2002/0098235 (2002-07-01), Dittmar et al.
patent: 2002/0192282 (2002-12-01), Beckert et al.
patent: 2005/0090473 (2005-04-01), Devane et al.
patent: 0 140 848 (1985-05-01), None
patent: 0 453 001 (1991-10-01), None
patent: 1 101 490 (2001-05-01), None
patent: 2692484 (1992-06-01), None
patent: WO 95/16451 (1995-06-01), None
patent: WO 00/76481 (2000-12-01), None
patent: WO 02/17887 (2002-03-01), None
Swift et al. Alimentary Pharmaceutical and Therapeutics, 1998, 6(2), 259-66. CAS Abstract Attached.
Swift et al. Alimentary Pharmaceutical and Therapeutics, 1998, 6(2), 259-66.
Swift et al. (Alimentary Pharmaceutical and Therapeutics, 1998, 6(2), 259-66).
Leopold, C.S. (Chapter 6 A Practical Approach in the Design of Colon-specific Drug Delivery Systems from Drug Targeting Organ-Specific Strategies 2001, Wiley-VCH Verlag GmbH 157-170).
Basit et al. (Business Briefing: Pharmatech May 2003, 185-190).
Jhala, et al., Studies on Toxicity and Tuberculostatic Behaviour of 4:4-Biazosalicylic Acid, Indian J. Pharm. 13, 3-5 (1951), pp. 3-5.
Khan, et al., A pH-Dependent Colon-Targeted Oral Drug Delivery System Using Methacrylic Acid Copolymers. II. Manipulation of Drug Release Using Eudragit® L100 and Eudragit S100 Combinations, Drug Development and Industrial Pharmacy, 26(5), 549-554 (2000).
International Search Report for PCT/IB2004/003059, mailed May 26, 2005.
“Azulfidine® sulfasalazine tablets, USP,” pp. 1-18, 2002.
“Dipentum® olsalazine sodium capsules,” pp. 1-17, 2001.
“Ulcerative Colitis (UC)—Clinical Presentation and Evolution Treatment,” Asacol.comMonograph: Introduction, , pp. 1-6, 2001.
Nugent, et al, “Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs,”Gut, 48:pp. 571-577, 2001.
“Asacol® (mesalamine) Delayed-Release Tablets,”Asacol(mesalamine), pp. 1-8, 2000.
“Pentasa® Sachet: Prolonged Release Granules 1g,” http://www.pentasa.com/site/ferring—com/view.asp?ID=510&printmode=3, pp. 1-4, 2001.
“Pentasa® Prolonged Release Tablets, 250 & 500 mg,” http://www.pentasa.com/site/ferring—com/view.asp?ID=522&printmode=3, pp. 1-4, 2001.
Kruis et al., “The Optimal Dose of 5-Aminosalicyclic Acid in Active Ulcerative Colitis: A Dose-Finding Study With Newly Developed Mesalamine,” Clinical Gastroenterology and Hepatology, vol. 1 pp. 36-43, (2003).
Mantzaris et al., “Budesonide Versus Mesalamine for Maintaining Remission in Patients Refusing Other Immunomodulators for Steroid-Dependent Crohn's Disease,” Clinical Gastroenterology and Hepatology , vol. 1, pp. 122-128, (2003).
S. Davaran et al., “Synthesis and Characterization of Methacrylic Derivatives of 5-Amino Salicylic Acid with pH-Sensitive Swelling Properties,” AAPS PharmaSciTech , vol. 2 (4) article 29 (2001).
Zambito et al., “Preparation and In Vitro Evaluation of Chitosan Matrices for Colonic Controlled Drug Delivery”, J Pharm Pharmaceut Sci, vol. 6 (2), pp. 274-281, (2003).
L. Sutherland et al., “Oral 5-Aminosalicylic Acid for Induction of Remission in Ulcerative Colitis (Review)”, Cochrane Database of Systematic Reviews 2006, Issue 2, Art. No. CD 000543.
M. Campieri et al., “Oral Beclometasone Dipropionate in the Treatment of Extensive and Left-Sided Active Ulcerative Colitis: A Multicentre Randomised Study,” Aliment Pharmacol Ther. vol. 17, pp. 1471-1480 (2003).
A. Forbes et al., “Review Article: Oral, Modified-Release Mesalazine Formulations-Proprietary Versus Generic,” Aliment Pharmacol Ther, vol. 17, pp. 1207-1214 (2003).
M. K. Chourasia et al., “Phamaceutical Approaches to Colon Targeted Drug Delivery Systems,” J. Pharm Pharmaceut Sci, vol. 6(1) pp. 33-66, (2003).
M. Brunner et al., “Gastrointestinal Transit and Release of 5-Aminosalicylic Acid From153Sm-Labelled Mesalazine Pellets vs. Tablets in Male Healthy Volunteers,” Aliment Pharmacol Ther, vol. 17 pp. 1163-1169, (2003).
I. R. Wilding et al., “Combined Scintigraphic and Pharmacokinetic Investigation of Enteric-Coated Mesalazine Micropellets in Heathy Subjects,” Aliment Pharmacol Ther, vol. 17, pp. 1153-1162, (2003).
Rogozina et al., “Comparative Efficacy of Mezakol and Sulfasalazine in Treating Chronic Relapsing Ulcerative Colitis,” Eksp Klin Gatroenterol, vol. 1, 58-9, 183 (2003), Abstract.
Fernandez-Banares et al., “Collagenous and Lymphocytic Colitis: Evaluation of Clinical and Histological Features, Response to Treatment, and Long-Term Follow-Up,” American Journal of Gastroenterology, vol. 98, No. 2, pp. 395-402, (2003).
M. Brunner et al., “Gastrointestinal Transit and 5-ASA Release From A New Mesalazine Extended-Release Formulation,” Aliment Pharmacol Ther, vol. 17, pp. 395-402, (2003).
Nigovic et al., “Determination of 5-Aminosalicylic Acid in Pharmaceutical Formulation by Differential Pulse Voltammetry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 31, pp. 169-174, (2003).
Tursi et al., “Assessment of Orocaecal Transit Time in Different Localization of Crohn's Disease and its Possbile Influence on Clinical Response to Therapy,” European Journal of Gastrenterology & Hepatology, vol. 15, No. 1, pp. 69-74, (2003).
L. Sutherland et al., “Oral 5-Aminosalicylic Acid for Maintenance of Remission in Ulcerative Colitis (Review),” Cochrane Database of Systematic Reviews 2006, issue2, At. No. CD 000544.
W. J. Sandborn et al., “Systematic Review: the Pharmacokinetic Profiles of Oral Mesalazine Formulations Mesalazine Pro-Drugs Used in the Management of Ulcerative Colitis,” Aliment Pharmacol Ther, vol. 17, pp. 29-42, (2003).
K.W. Schroeder, “Role of Mesalazine in Acute and Long-Term Treatment of Ulcerative Colitis and Its Complications,” Scand J. Gastroenterol, Suppl. 236 pp. 42-47, (2002).
G. Dijkstra et al., “Blockade of NF-κB Activation and Donation of Nitric Oxide: New Treatment Options in Inflammatory Bowel Disease?,” Scan J Gastroenterol, Suppl. 236 (2002).
K. McKeage et al., “Budesonide (Entocort® EC Capsules)A Review of Its

Affiliated with

Also associated with

Rating

Formulations and methods of treating inflammatory bowel disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulations and methods of treating inflammatory bowel disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations and methods of treating inflammatory bowel disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4215315